Lightnews — Scholar-powered news

Reposted by Tom Newsom-Davis

Simon Kuestenmacher @simongerman600.bsky.social · May 10

There is healthy skepticism and there is this...

Tom Newsom-Davis @tnewsomdavis.bsky.social · May 9

Going through applications for BTOG Trainee Representatives in oncology and respiratory medicine

The most extraordinary group of dynamic, motivated, committed individuals

So impressive
So hard to decide
Every single one would be excellent

a man with a beard is standing in front of a microphone scratching his head

ALT: a man with a beard is standing in front of a microphone scratching his head

media.tenor.com

1

Reposted by Tom Newsom-Davis

Lung Cancer Research Foundation @lcrf.org · Apr 16

On our next livestreams: a look at how #LungCancer affects young people and women, with moderator Dr. Isabel Preeshagul.

Wed, April 23: Young Lung Cancer w/ Dr. Eric Singhi @lungoncdoc.bsky.social, LCRF.org/together2
Wed, May 14: Women & Lung Cancer w/ Dr. Narjust Florez, LCRF.org/together

3 6

Reposted by Tom Newsom-Davis

Florez Lab @florezlab.bsky.social · Apr 3

Exciting news!
@curetoday.bsky.social is hosting an incredible Young-Onset Lung Cancer Summit 🎉 Chaired by the amazing
@lungoncdoc.bsky.social, this is a must-attend event for anyone looking to learn more about @younglungcancer.bsky.social!

1 2 2

Reposted by Tom Newsom-Davis

Igor Randulfe @randulfe.bsky.social · Apr 22

Happy to share our latest work, led by Dr Monaca. In a time-dependent analysis, we show that irAEs are associated with improved outcomes in ES-SCLC. Interestingly, neither high-grade irAEs nor the use of steroids appeared to negatively impact survival. www.sciencedirect.com/science/arti...

1 1

Tom Newsom-Davis @tnewsomdavis.bsky.social · Apr 22

Not only does ‘Repositories of Agriculture’ debase scientific publications through unsolicited paper requests, but they then get aggressive when you don’t reply.

Extraordinary

Think they need to review their PR skills (and conscience)

Reposted by Tom Newsom-Davis

Itai Yanai @itaiyanai.bsky.social · Apr 16

When the conference organizers ask if you can send in your slides a week in advance

4 30 200

Tom Newsom-Davis @tnewsomdavis.bsky.social · Apr 10

❗️FLAURA2 approved by NICE❗️

Already on BlueTeq!

Now an option for 1L EGFR+ pts

Worth familiarising yourself with the higher risk subgroups that seemed to better with this regimen

BTOG @btog.bsky.social · Apr 10

NICE has recommended Osimertinib with pemetrexed and platinum-based chemotherapy (based on the FLAURA2 trial) as an option for untreated advanced NSCLC in adults whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

3 5

Tom Newsom-Davis @tnewsomdavis.bsky.social · Apr 9

🏴󠁧󠁢󠁳󠁣󠁴󠁿?

1

Tom Newsom-Davis @tnewsomdavis.bsky.social · Apr 9

❗️BTOG / NLCA ‘State of the Nation’ webinar on 15th May❗️

The National Lung Cancer Audit has been instrumental in improvement of lung cancer outcomes in UK

Come and hear about our successes and challenges. Neal Navani always gives a beautifully clear and concise talk. 👍

3 3

Tom Newsom-Davis @tnewsomdavis.bsky.social · Apr 6

This is an excellent series of discussions. Informed and informative. Highly recommend it.

@katherinesleeman.bsky.social especially good, as she is always.

Prof Erica Borgstrom @ericaborgstrom.bsky.social · Apr 1

Today's episode of Inside Health (BBC R4) asks how could we be certain someone wants to die, who brings up the conversation & safeguarding.
I was part of the panel discussion with @profmarktaubert.bsky.social @katherinesleeman.bsky.social & @drdavidnicholl.bsky.social
www.bbc.co.uk/sounds/play/...

Inside Health - Assisted dying: How could we be certain someone wants to die? - BBC Sounds

James Gallagher and the panel discuss the safeguarding implications of the proposed bill.

www.bbc.co.uk

1 3

Reposted by Tom Newsom-Davis

Sanjay Popat @drsanjaypopat.bsky.social · Apr 5

Very important dataset and a set forward to potential ambulatory delivery in the future.

Dr. Herbert Loong @herbloongmd.bsky.social · Apr 5

Happy to share our recent #ESMOOpen paper on the #safety and #feasibility of #outpatient administration of #tarlatamab as part of the #DeLLphi300 study providing evidence that support less intensive monitoring at initiation of therapy. #LCSM 🫁 #SCLC 😀

doi.org/10.1016/j.es...

1 3

Tom Newsom-Davis @tnewsomdavis.bsky.social · Apr 4

🧐 Are you a 🇬🇧 Healthcare Professional treating lung cancer?

🤔 Do you want to learn how clinical research runs, whilst advancing your career?

💥 Be an Associate PI of a trial!

🥳 eVOLVE-Lung02 (I am 🇬🇧 CI) accepted into NIHR Associate PI programme

Details here 👇
www.nihr.ac.uk/career-devel...

www.nihr.ac.uk

3 7

Tom Newsom-Davis @tnewsomdavis.bsky.social · Mar 31

UK Oncologist’s Garden:

The pear trees are just in blossom

1

Reposted by Tom Newsom-Davis

Simon Kuestenmacher @simongerman600.bsky.social · Mar 30

What!? Tiramisu is younger than my dad? Also the 1940s saw great additions to our cuisine. Weird how young ciabatta is! Fun chart shows several foods that were invented surprisingly recently. Source: buff.ly/nvQgUns

8 14 79

Tom Newsom-Davis @tnewsomdavis.bsky.social · Mar 29

Wow
Extraordinary times

Gregory Riely @rielymd.bsky.social · Mar 29

Peter Marks leaving FDA. “However it has become clear that truth and transparency are not desired by the Secretary, but rather he wishes subservient confirmation of his misinformation and lies.” From Bloomberg. apple.news/AIvBYR8IDQru...

1 1

Tom Newsom-Davis @tnewsomdavis.bsky.social · Mar 28

‘No evidence that patient survival is improved with surgery’

Curious wording from NCCN, given that MARS2 found that epithelioid histology pts had 12% higher risk of death if they had surgery…

Reposted by Tom Newsom-Davis

EGFR Positive Lung Cancer UK @egfrpositiveuk.bsky.social · Mar 28

New data from the LAURA trial shared at #ELCC25 today shows promising results for Stage 3 unresectable EGFR+ #lungcancer.

Giving osimertinib after chemoradiation meant people went much longer before needing further treatment — over 40 months, compared to just 9 months without it. #LCSM

2 5

Tom Newsom-Davis @tnewsomdavis.bsky.social · Mar 28

Predicting surgical complexity following neo-adjuvant chemoIO

Single centre 🇬🇧 study

👉 43% defined as complex

🔺 Risk score includes x3 variables:
❇️ CN2
❇️ Absence of nodal response
❇️ PD-L1 >50%

#ELCC25

2

Tom Newsom-Davis @tnewsomdavis.bsky.social · Mar 28

LAURA OS update (LBA4)
👉 Now 31% maturity

❇️ 78% in PBO grp got Osi at PD
❇️ Improved PFS2
❇️ Trend ⬆️ OS HR 0.67, not significant

💭 Confirm activity of Osi
💭 Crossover impacts OS difference
💭 Final maturity due @ 60%
💭 Surprised 1/3 Osi pts = no further treatment at PD

#ELCC25

2 3 4

Reposted by Tom Newsom-Davis

Dr Colin Lindsay @drcolinlindsay.bsky.social · Mar 27

2) daraxonrasib (rmc-6236) offering early phase and v impressive activity in g12d g12v 2nd line nsclc. RR 38% and mPFS >10m. V tolerable toxicity profile again. Next will be IO combos, congrats+++ to Revolution Medicines and the investigators. #ELCC25

3 4

Reposted by Tom Newsom-Davis

Dr Colin Lindsay @drcolinlindsay.bsky.social · Mar 27

1) KRYSTAL-7 update on pembro+adagrasib in 1st line pdl1 >50% nsclc. Tox to navigate but mPFS >27m! Further reinforcing the view that ras orchestrates TME, not just cancer cell intrinsic pathways. Massive congrats to investigators, mirati, bms #ELCC25

5 6

Tom Newsom-Davis @tnewsomdavis.bsky.social · Mar 27

Great ROS1 TKI summary slide from Julian Mazieres

2 4

Tom Newsom-Davis @tnewsomdavis.bsky.social · Mar 27

COCOON: mitigating cutaneous toxicity of Amivantamab

✅ 60% reduction in Gr2+ dermatology AE
✅ Reduction scalp issues+ paronychia
✅ Fewer Ami dose amendments needed

💭 This regimen should be instigated immediately for any patient starting Amivantamab based therapy

#ELCC25

3 3

Tom Newsom-Davis @tnewsomdavis.bsky.social · Mar 27

Case controlled indirect comparison of Taletrectinib v Crizotinib in ROS1 NSCLC

👉 From TRUST I + II / PROFILE 1091 trials
✅ ORR 90% v 71%
✅ Improved PFS, HR 0.48
👉 Similar Gr3 TRAEs

💭 Ph3 head-2-head ongoing
💭 In meanwhile, this suggests Taletrectinib superior
💭 Would like to see CNS data

#ELCC25

1 1 4